How are AI-designed drugs finally reaching patients?

The answer

In 2025-2026, the biotech industry reached a landmark moment as several drug candidates discovered and optimized entirely by AI entered mid-to-late-stage clinical trials for the first time. Companies like Insilico Medicine, Recursion, and Isomorphic Labs (a Google DeepMind spinoff) advanced AI-designed molecules through human testing for conditions including cancer, fibrosis, and inflammatory diseases. The shift from computational proof-of-concept to tangible medical results validated years of investment in AI-driven drug discovery. Traditional drug development takes 10–15 years and costs $2.6 billion per approved drug. AI promises to compress timelines to 3–5 years by rapidly screening billions of molecular candidates and predicting their behavior before any lab work begins.